March 12, 2019 PAP-Q1-2019-NI-009
2018 YEAR IN REVIEW
Through our Analytics suite available on PharmasAlmanac.com, we are able to capture data on the traffic through our content portal. This includes the articles, companies, contributors and topics that have received the most views among our audience of industry professionals.
Here, we present some of this digital data analysis for readers of our print magazine, showcasing the most-read articles across the entire pharmaceutical supply chain (from CDMOs, CROs, excipients, equipment and logistics), as well as specific industry segments and specialty topics of interest.
Among our own content authored by members of the Nice Insight team, we had the greatest impact with the three-part features from our first and second quarter issues of Pharma’s Almanac, which explored mergers and acquisitions activity and next-generation biologics therapies, respectively.
Additionally, we are highlighting the companies and individual contributors who have generated the most interactions on our site over the last year, as well as the trending topics that have made the greatest overall impressions in the first quarter of 2019.
We are proud to have had the privilege of developing and publishing such a diversity of insightful Thought Leadership content covering subjects of the highest value to our readers throughout pharma and supporting industries, and we are enthusiastic about the opportunity to continue to support our community as the industry continues to evolve in 2019 and beyond.
Encapsulation: “Overcoming Formulation Challenges with Liquid-fill Capsules,” Eli Elias, CapsCanada
Artificial Intelligence: “Artificial Intelligence in Biopharmaceutical Manufacturing,” Constantin Loghinov, MILS Group LLC
M&A: “Inside Mergers & Acquisitions,” Kevin Bottomley, Results Healthcare
Parenterals: “Expanding U.S. Supply Options for Large-Volume Parenterals,” Marga Viñes, Grifols
Formulation: “The Coming of Age of Amorphous Solid Dispersions,” Márcio Temtem, Ph.D., Hovione
OSD: “Scientific Expertise Facilitates Oral Peptide Product Development and Manufacturing,” Ariana Nagel & Matthew Ferrell, UPM Pharmaceuticals
Fermentation: “Focused on Fermentation,” Elise Mous & Thomas De Maria, Capua Bioservices
API: "Meeting the Need for Small-Volume API Manufacturing,” Jim Scandura, Avara Pharmaceutical Services
Biologics: "Fully Supporting Customer Needs for Biologics Development and Manufacturing,” James Park, Samsung Biologics
Cell & Gene Therapy: "Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing,” Richard Snyder, Ph.D., Christopher Murphy, Susan D’Costa Ph.D., & Cameron Jones, Brammer Bio
Engineering: "Death to Cleanrooms in Biopharmaceutical Manufacturing,” Mark Pelletier, Ph.D., CRB USA
Standalone CDMO: “Providing Flexible Capabilities to Meet Market Demand for Sterile Fill-Finish Services,” Andrea Baiocchi, Avara Pharmaceutical Services
Embedded CDMO: “Why Business Continuity Management is Important for CDMOs,” Mayeul Cauvin, Servier
1. Avara Pharmaceutical Services |
2. Federal Equipment Company |
3. Servier |
4. Marken |
5. Hovione |
6. Alcami |
7. UPM Pharmaceuticals |
8. CRB USA |
9. Brammer Bio |
10. CapsCanada |
11. BioVectra |
12. AMRI |
13. Catalent |
14. GSK Contract Manufacturing |
15. Almac |
16. AbbVie Contract Manufacturing |
17. Patheon |
18. Grifols |
19. Piramal Pharma Solutions |
20. WuXi AppTec |
CDMO: “Providing Flexible Capabilities to Meet Market Demand for Sterile Fill-Finish Services,” Andrea Baiocchi, Avara Pharmaceutical Services
CRO: “Creating Comprehensive Solutions through Laboratory Testing,” Xin Zhang, Ph.D., WuXi AppTec
Excipients: “Investing in New Technologies for Innovative Functional Solutions,” Sarath Chandar, SPI Pharma
Pharma Equipment: “Microbial and Biological Decontamination of Equipment Brings Peace of Mind,” Matt Hicks, Federal Equipment Company
Logistics: “Overcoming Challenges in the Complex Market for Clinical Trials and Clinical Logistics,” Wes Wheeler, Marken
+ Parenteral manufacturing
+ CDMO
+ Cell & gene therapy
+ Biologics – large molecule
+ Packaging
+ Innovation
+ Continuous Manufacturing
+ Logistics
+ CRO
+ Automation
+ Regulatory
+ API – small molecule
+ Outsourcing
+ Excipients
Richard Snyder, Ph.D., CSO/Founder, & Mark Bamforth, CEO/Founder, Brammer Bio
Mark Pelletier, Ph.D., Director, CRB USA
Marga Viñes, Business Development Manager, Grifols
Syed T. Husain, CCO, Alcami
Wes Wheeler, CEO, Marken
Peter Walters, Lead Process Engineer, CRB USA
Ramesh Subramian, VP, Strategic Marketing & Global Head, Business Development, Piramal Pharma Solutions
Andrew Bulpin, Head of Process Solutions Strategic, Marketing and Innovation, Millipore Sigma
Matt Hicks, COO & Counsel, Federal Equipment Company
Doug Krafte, Ph.D., Chief Scientific Officer, Icagen
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.